- Reproduction biotechnology and bio-separations company Memphasys (MEM) enters a mid-week trading halt ahead of a capital raising
- The company will remain in the trading halt until Friday, July 29, or when further details are released to the market, whichever occurs first
- Prior to entering the trading halt, Memphasys announced it had enrolled and treated the first couple under a clinical IVF study trialling its Felix device
- The study is assessing the safety and performance of Felix vs swim-up and density gradient centrifugation for couples suffering from male infertility
- Shares in Memphasys last traded at 4.5 cents on July 25
Reproduction biotechnology and bio-separations company Memphasys (MEM) has entered a mid-week trading halt ahead of a capital raising.
The company will remain in the trading halt until Friday, July 29, or when it releases further details to the market, whichever occurs first.
Memphasys is yet to disclose how much it intends to raise or for what it will use the funds once received.
Prior to entering the trading halt, Memphasys announced it had enrolled and treated the first couple under a clinical in-vitro fertilisation (IVF) study trialling its Felix device.
The study is assessing the safety and performance of the Felix device vs swim-up and density gradient centrifugation for couples suffering from male infertility, to isolate sperm from semen.
Felix is Memphasys’ novel device that quickly and gently separates high-quality sperm from semen.
The data from the study will be submitted to the Therapeutic Goods Administration so Felix can be sold in Australia.
Shares in Memphasys last traded at 4.5 cents on July 25. The company has a $35.65 million market cap.